Cited 0 times in Scipus Cited Count

Exploration of the Sphingolipid Metabolite, Sphingosine-1-phosphate and Sphingosine, as Novel Biomarkers for Aspirin-exacerbated Respiratory Disease

DC Field Value Language
dc.contributor.authorTrinh, HK-
dc.contributor.authorKim, SC-
dc.contributor.authorCho, K-
dc.contributor.authorKim, SJ-
dc.contributor.authorBan, GY-
dc.contributor.authorYoo, HJ-
dc.contributor.authorCho, JY-
dc.contributor.authorPark, HS-
dc.contributor.authorKim, SH-
dc.date.accessioned2018-05-04T00:24:49Z-
dc.date.available2018-05-04T00:24:49Z-
dc.date.issued2016-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/14917-
dc.description.abstractSphingolipid (SL) metabolites have been suggested to be important inflammatory mediators in airway inflammation and asthma. However, little is known about SL metabolites in aspirin-exacerbated respiratory disease (AERD). We aimed to explore the potential AERD biomarkers by conducting lipidomics targeting SL metabolites. The levels of SL metabolites in serum and urine samples from 45 AERD patients and 45 aspirin-tolerant asthma (ATA) patients were quantified through mass spectrometry. During the lysine-aspirin bronchoprovocation test (ASA-BPT), the levels of serum sphingomyelin (SM) were significantly decreased in AERD (P < 0.05) but not in ATA. The serum SM levels were positively correlated with airway responsiveness to methacholine. At the basal status before the ASA-BPT, the levels of serum sphingosine-1-phosphate (S1P) and urine sphingosine were significantly higher in the AERD patients compared with that of ATA patients (P < 0.001) and were positively correlated with a greater decrease in FEV1 (%) values following the ASA-BPT test (P < 0.001 for each), and with serum periostin level (P < 0.05 for each). This study is the first to evaluate serum S1P and urine sphingosine as potential biomarkers of AERD as well as to examine the metabolic disturbance of SL in AERD patients.-
dc.language.isoen-
dc.titleExploration of the Sphingolipid Metabolite, Sphingosine-1-phosphate and Sphingosine, as Novel Biomarkers for Aspirin-exacerbated Respiratory Disease-
dc.typeArticle-
dc.identifier.pmid27830727-
dc.identifier.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5103193/-
dc.contributor.affiliatedAuthor반, 가영-
dc.contributor.affiliatedAuthor박, 해심-
dc.contributor.affiliatedAuthor김, 승현-
dc.type.localJournal Papers-
dc.identifier.doi10.1038/srep36599-
dc.citation.titleScientific reports-
dc.citation.volume6-
dc.citation.date2016-
dc.citation.startPage36599-
dc.citation.endPage36599-
dc.identifier.bibliographicCitationScientific reports, 6. : 36599-36599, 2016-
dc.identifier.eissn2045-2322-
dc.relation.journalidJ020452322-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Allergy
Journal Papers > Hospital > Clinical Trial Center
Files in This Item:
27830727.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse